CA2090453A1 - Remedy for osteoporosis - Google Patents

Remedy for osteoporosis

Info

Publication number
CA2090453A1
CA2090453A1 CA002090453A CA2090453A CA2090453A1 CA 2090453 A1 CA2090453 A1 CA 2090453A1 CA 002090453 A CA002090453 A CA 002090453A CA 2090453 A CA2090453 A CA 2090453A CA 2090453 A1 CA2090453 A1 CA 2090453A1
Authority
CA
Canada
Prior art keywords
osteoporosis
group
csf
bone
remedy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002090453A
Other languages
English (en)
French (fr)
Inventor
Takuji Hanamura
Lyang-Ja Lee
Yasushi Matsuoka
Masanori Sugiura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Green Cross Corp Japan
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Morinaga Milk Industry Co Ltd filed Critical Green Cross Corp Japan
Publication of CA2090453A1 publication Critical patent/CA2090453A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002090453A 1991-07-08 1992-07-07 Remedy for osteoporosis Abandoned CA2090453A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3-192714 1991-07-08
JP3192714A JPH0517367A (ja) 1991-07-08 1991-07-08 骨粗鬆症治療剤

Publications (1)

Publication Number Publication Date
CA2090453A1 true CA2090453A1 (en) 1993-01-09

Family

ID=16295841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090453A Abandoned CA2090453A1 (en) 1991-07-08 1992-07-07 Remedy for osteoporosis

Country Status (5)

Country Link
EP (1) EP0547234A1 (enExample)
JP (1) JPH0517367A (enExample)
KR (1) KR930702016A (enExample)
CA (1) CA2090453A1 (enExample)
WO (1) WO1993000921A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081353A1 (en) * 2008-03-14 2011-04-07 Haegel Helene Antibody against the csf-1 r
US9428584B2 (en) 2008-03-14 2016-08-30 Transgene S.A. Antibody against the CSF-1R

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100484569C (zh) * 2001-11-19 2009-05-06 协和发酵工业株式会社 将多潜能干细胞从组织中流通到外周血的药物
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638204B2 (en) * 1987-11-12 1993-06-24 Schering Corporation Acceleration of bone formation with gm-csf
JPH022391A (ja) * 1988-02-08 1990-01-08 Otsuka Pharmaceut Co Ltd ヒトｍ―ｃｓｆ及びその製造法
DE69022606T2 (de) * 1989-02-28 1996-05-02 Morinaga Milk Industry Co Ltd Menschlichen Monozyt-Makrophagen-Koloniestimulierungsfaktor enthaltende Zusammensetzung.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081353A1 (en) * 2008-03-14 2011-04-07 Haegel Helene Antibody against the csf-1 r
US8604170B2 (en) * 2008-03-14 2013-12-10 Transgene S.A. Antibody against the CSF-1R
US9221912B2 (en) 2008-03-14 2015-12-29 Transgene S.A. Antibody against the CSF-1R
US9428584B2 (en) 2008-03-14 2016-08-30 Transgene S.A. Antibody against the CSF-1R
US9982055B2 (en) 2008-03-14 2018-05-29 Transgene S.A. Antibody against the CSF-1R

Also Published As

Publication number Publication date
WO1993000921A1 (en) 1993-01-21
JPH0517367A (ja) 1993-01-26
KR930702016A (ko) 1993-09-08
EP0547234A1 (en) 1993-06-23
EP0547234A4 (enExample) 1994-02-09

Similar Documents

Publication Publication Date Title
EP0436469B1 (en) Composition and method for the treatment of osteoporosis in mammals
AU686628B2 (en) Parathyroid Hormone and Raloxifene for Increasing Bone Mass
DE69835823T2 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
US6087338A (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
BG62556B1 (bg) Състав за лечение на респираторен дистрес синдром приновородени и на акутен респираторен дистрес
US6300309B1 (en) Method and composition for the treatment of osteoporosis
CA2142455A1 (en) Method for systemic treatment of catabolic conditions and systemic tissue injury
JP2934023B2 (ja) コルチコステロイド治療組成物
DE60128399T2 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
CA2090453A1 (en) Remedy for osteoporosis
FORTIER et al. A comparative study of some of the chemical and morphological changes elicited in the adrenals by stress and purified ACTH
US8921312B2 (en) Combination of insulin and ascorbate to enhance wound healing
CA2233071C (en) Use of growth hormone for recovering renal function
Hint et al. Chronic toxicity of dextran sulphate in rabbits
DE60005188T2 (de) Grf-haltige lyophilisierte arzneizusammensetzungen
JPH07101877A (ja) 血小板減少症治療剤
WO1998041222A1 (en) Obesity protein formulations
JPH07149659A (ja) 骨損傷治療剤
WO2007145934A1 (en) Combination of insulin and ascorbate to enhance wound healing
HK1013800B (en) Parathyroid hormone and raloxifene for increasing bone mass
HU204711B (en) Process for producing pharmaceutical compositions comprising gamma-interferon and suitable for treating cancer of ovary

Legal Events

Date Code Title Description
FZDE Dead